25 XP   0   0   10

Rigel Pharmaceuticals Inc
Buy, Hold or Sell?

Let's analyse Rigel together

PenkeI guess you are interested in Rigel Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Rigel Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Rigel Pharmaceuticals Inc

I send you an email if I find something interesting about Rigel Pharmaceuticals Inc.

Quick analysis of Rigel (30 sec.)










What can you expect buying and holding a share of Rigel? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$-0.16
Expected worth in 1 year
$-0.51
How sure are you?
20.0%

+ What do you gain per year?

Total Gains per Share
$-0.34
Return On Investment
-28.6%

For what price can you sell your share?

Current Price per Share
$1.20
Expected price per share
$0.9098 - $1.77
How sure are you?
50%

1. Valuation of Rigel (5 min.)




Live pricePrice per Share (EOD)

$1.20

Intrinsic Value Per Share

$-0.67 - $1.33

Total Value Per Share

$-0.84 - $1.17

2. Growth of Rigel (5 min.)




Is Rigel growing?

Current yearPrevious yearGrowGrow %
How rich?-$28.6m-$13.6m-$15m-52.5%

How much money is Rigel making?

Current yearPrevious yearGrowGrow %
Making money-$25m-$61.5m$36.5m145.5%
Net Profit Margin-21.5%-51.2%--

How much money comes from the company's main activities?

3. Financial Health of Rigel (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#967 / 1007

Most Revenue
#194 / 1007

Most Profit
#476 / 1007

Most Efficient
#488 / 1007

What can you expect buying and holding a share of Rigel? (5 min.)

Welcome investor! Rigel's management wants to use your money to grow the business. In return you get a share of Rigel.

What can you expect buying and holding a share of Rigel?

First you should know what it really means to hold a share of Rigel. And how you can make/lose money.

Speculation

The Price per Share of Rigel is $1.2. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Rigel.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Rigel, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-0.16. Based on the TTM, the Book Value Change Per Share is $-0.09 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.25 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Rigel.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.14-11.9%-0.14-11.9%-0.33-27.8%-0.23-18.8%-0.32-26.5%
Usd Book Value Change Per Share-0.09-7.1%-0.09-7.1%-0.25-20.9%-0.16-13.2%-0.14-11.3%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.09-7.1%-0.09-7.1%-0.25-20.9%-0.16-13.2%-0.14-11.3%
Usd Price Per Share1.45-1.45-1.50-2.25-2.51-
Price to Earnings Ratio-10.14--10.14--4.49--13.37--10.20-
Price-to-Total Gains Ratio-16.92--16.92--5.98--37.58--16.02-
Price to Book Ratio-8.88--8.88--19.32-2.42-3.91-
Price-to-Total Gains Ratio-16.92--16.92--5.98--37.58--16.02-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.2
Number of shares833
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.09-0.16
Usd Total Gains Per Share-0.09-0.16
Gains per Quarter (833 shares)-71.37-131.57
Gains per Year (833 shares)-285.47-526.27
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-285-2950-526-536
20-571-5800-1053-1062
30-856-8650-1579-1588
40-1142-11500-2105-2114
50-1427-14350-2631-2640
60-1713-17200-3158-3166
70-1998-20050-3684-3692
80-2284-22900-4210-4218
90-2569-25750-4736-4744
100-2855-28600-5263-5270

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.010.00.00.0%1.024.00.04.0%
Book Value Change Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%2.08.00.020.0%12.013.00.048.0%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.010.00.0%0.00.025.00.0%
Total Gains per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%2.08.00.020.0%12.013.00.048.0%

Fundamentals of Rigel

About Rigel Pharmaceuticals Inc

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.

Fundamental data was last updated by Penke on 2024-05-04 02:23:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just not able to pay all its debts by selling its assets.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Rigel Pharmaceuticals Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Rigel earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Rigel to the Biotechnology industry mean.
  • A Net Profit Margin of -21.5% means that $-0.21 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Rigel Pharmaceuticals Inc:

  • The MRQ is -21.5%. The company is making a huge loss. -2
  • The TTM is -21.5%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-21.5%TTM-21.5%0.0%
TTM-21.5%YOY-51.2%+29.8%
TTM-21.5%5Y-45.0%+23.5%
5Y-45.0%10Y-374.2%+329.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-21.5%-207.2%+185.7%
TTM-21.5%-216.8%+195.3%
YOY-51.2%-282.4%+231.2%
5Y-45.0%-426.4%+381.4%
10Y-374.2%-589.3%+215.1%
1.1.2. Return on Assets

Shows how efficient Rigel is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Rigel to the Biotechnology industry mean.
  • -21.4% Return on Assets means that Rigel generated $-0.21 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Rigel Pharmaceuticals Inc:

  • The MRQ is -21.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -21.4%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-21.4%TTM-21.4%0.0%
TTM-21.4%YOY-45.9%+24.5%
TTM-21.4%5Y-30.1%+8.7%
5Y-30.1%10Y-45.3%+15.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-21.4%-13.0%-8.4%
TTM-21.4%-12.5%-8.9%
YOY-45.9%-11.2%-34.7%
5Y-30.1%-13.6%-16.5%
10Y-45.3%-15.2%-30.1%
1.1.3. Return on Equity

Shows how efficient Rigel is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Rigel to the Biotechnology industry mean.
  • 0.0% Return on Equity means Rigel generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Rigel Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-54.4%+54.4%
5Y-54.4%10Y-66.7%+12.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--16.6%+16.6%
TTM--15.7%+15.7%
YOY--14.2%+14.2%
5Y-54.4%-18.9%-35.5%
10Y-66.7%-19.9%-46.8%

1.2. Operating Efficiency of Rigel Pharmaceuticals Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Rigel is operating .

  • Measures how much profit Rigel makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Rigel to the Biotechnology industry mean.
  • An Operating Margin of -15.6% means the company generated $-0.16  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Rigel Pharmaceuticals Inc:

  • The MRQ is -15.6%. The company is operating very inefficient. -2
  • The TTM is -15.6%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-15.6%TTM-15.6%0.0%
TTM-15.6%YOY-45.1%+29.5%
TTM-15.6%5Y-42.0%+26.4%
5Y-42.0%10Y-378.6%+336.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-15.6%-285.4%+269.8%
TTM-15.6%-226.2%+210.6%
YOY-45.1%-288.4%+243.3%
5Y-42.0%-469.6%+427.6%
10Y-378.6%-599.3%+220.7%
1.2.2. Operating Ratio

Measures how efficient Rigel is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1.18 means that the operating costs are $1.18 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Rigel Pharmaceuticals Inc:

  • The MRQ is 1.175. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.175. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.175TTM1.1750.000
TTM1.175YOY1.451-0.276
TTM1.1755Y1.424-0.248
5Y1.42410Y7.131-5.707
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.1753.231-2.056
TTM1.1753.303-2.128
YOY1.4513.763-2.312
5Y1.4245.586-4.162
10Y7.1317.464-0.333

1.3. Liquidity of Rigel Pharmaceuticals Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Rigel is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 1.86 means the company has $1.86 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Rigel Pharmaceuticals Inc:

  • The MRQ is 1.864. The company is able to pay all its short-term debts. +1
  • The TTM is 1.864. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.864TTM1.8640.000
TTM1.864YOY1.777+0.086
TTM1.8645Y2.059-0.195
5Y2.05910Y3.956-1.897
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.8643.855-1.991
TTM1.8644.160-2.296
YOY1.7775.323-3.546
5Y2.0596.122-4.063
10Y3.9566.480-2.524
1.3.2. Quick Ratio

Measures if Rigel is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Rigel to the Biotechnology industry mean.
  • A Quick Ratio of 2.10 means the company can pay off $2.10 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Rigel Pharmaceuticals Inc:

  • The MRQ is 2.096. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 2.096. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.096TTM2.0960.000
TTM2.096YOY2.028+0.067
TTM2.0965Y2.723-0.627
5Y2.72310Y6.259-3.536
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.0963.506-1.410
TTM2.0964.001-1.905
YOY2.0285.390-3.362
5Y2.7236.127-3.404
10Y6.2596.488-0.229

1.4. Solvency of Rigel Pharmaceuticals Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Rigel assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Rigel to Biotechnology industry mean.
  • A Debt to Asset Ratio of 1.24 means that Rigel assets are financed with 124.4% credit (debt) and the remaining percentage (100% - 124.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Rigel Pharmaceuticals Inc:

  • The MRQ is 1.244. The company is just not able to pay all its debts by selling its assets. -1
  • The TTM is 1.244. The company is just not able to pay all its debts by selling its assets. -1
Trends
Current periodCompared to+/- 
MRQ1.244TTM1.2440.000
TTM1.244YOY1.101+0.143
TTM1.2445Y0.898+0.346
5Y0.89810Y0.563+0.336
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.2440.344+0.900
TTM1.2440.339+0.905
YOY1.1010.275+0.826
5Y0.8980.368+0.530
10Y0.5630.389+0.174
1.4.2. Debt to Equity Ratio

Measures if Rigel is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Rigel to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Rigel Pharmaceuticals Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y1.699-1.699
5Y1.69910Y1.001+0.698
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.390-0.390
TTM-0.408-0.408
YOY-0.341-0.341
5Y1.6990.438+1.261
10Y1.0010.469+0.532

2. Market Valuation of Rigel Pharmaceuticals Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Rigel generates.

  • Above 15 is considered overpriced but always compare Rigel to the Biotechnology industry mean.
  • A PE ratio of -10.14 means the investor is paying $-10.14 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Rigel Pharmaceuticals Inc:

  • The EOD is -8.389. Based on the earnings, the company is expensive. -2
  • The MRQ is -10.137. Based on the earnings, the company is expensive. -2
  • The TTM is -10.137. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-8.389MRQ-10.137+1.748
MRQ-10.137TTM-10.1370.000
TTM-10.137YOY-4.492-5.645
TTM-10.1375Y-13.365+3.229
5Y-13.36510Y-10.202-3.164
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-8.389-2.351-6.038
MRQ-10.137-2.599-7.538
TTM-10.137-2.762-7.375
YOY-4.492-4.025-0.467
5Y-13.365-6.305-7.060
10Y-10.202-6.538-3.664
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Rigel Pharmaceuticals Inc:

  • The EOD is -10.147. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -12.261. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -12.261. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-10.147MRQ-12.261+2.114
MRQ-12.261TTM-12.2610.000
TTM-12.261YOY-3.546-8.716
TTM-12.2615Y10.498-22.760
5Y10.49810Y0.370+10.128
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-10.147-3.010-7.137
MRQ-12.261-3.306-8.955
TTM-12.261-3.607-8.654
YOY-3.546-5.524+1.978
5Y10.498-8.299+18.797
10Y0.370-8.910+9.280
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Rigel is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of -8.88 means the investor is paying $-8.88 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Rigel Pharmaceuticals Inc:

  • The EOD is -7.348. Based on the equity, the company is expensive. -2
  • The MRQ is -8.879. Based on the equity, the company is expensive. -2
  • The TTM is -8.879. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-7.348MRQ-8.879+1.531
MRQ-8.879TTM-8.8790.000
TTM-8.879YOY-19.323+10.444
TTM-8.8795Y2.424-11.303
5Y2.42410Y3.906-1.482
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-7.3482.019-9.367
MRQ-8.8792.116-10.995
TTM-8.8792.099-10.978
YOY-19.3232.873-22.196
5Y2.4243.556-1.132
10Y3.9063.946-0.040
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Rigel Pharmaceuticals Inc.

3.1. Institutions holding Rigel Pharmaceuticals Inc

Institutions are holding 61.357% of the shares of Rigel Pharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Armistice Capital, LLC9.74890.338517100000-36000-0.2101
2023-12-31BlackRock Inc8.66460.0006151980777845825.4434
2023-12-31Morgan Stanley - Brokerage Accounts8.2410.0019144551147472639107.0199
2023-12-31Soleus Capital Management, L.P.5.38331.51929442579-5360436-36.2118
2023-12-31Vanguard Group Inc5.10430.00038953217854670.9638
2023-12-31Acadian Asset Management LLC2.63490.0264621764-38976-0.8363
2023-12-31Geode Capital Management, LLC2.10520.000636926991455994.1047
2023-12-31State Street Corporation2.0410.00033580077763872.1802
2023-09-30Jacobs Levy Equity Management, Inc.1.92070.02163369076-202085-5.6588
2023-12-31Nuveen Asset Management, LLC1.40630.0012246666866360.2698
2023-12-31ING Investment Management LLC1.19330.00362093019359231.7463
2024-03-31Assenagon Asset Management SA1.13530.007199139800
2023-12-31CM Management, LLC0.96921.981170000020000013.3333
2023-12-31Macquarie Group Ltd0.91220.0027160000000
2023-12-31Northern Trust Corp0.87890.00041541604239741.5797
2023-12-31GSA Capital Partners LLP0.81360.174142704245560146.8995
2023-12-31Renaissance Technologies Corp0.75150.003131822618640016.469
2023-12-31Sphera Funds Management Ltd.0.70020.2866122812600
2023-12-31Goldman Sachs Group Inc0.58350.0001102347443825774.8879
2023-12-31UBS O'Connor LLC0.51270.0938899335-252430-21.9168
Total 55.70064.462497701495+4021538+4.1%

3.2. Funds holding Rigel Pharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-03-31Vanguard Total Stock Mkt Idx Inv3.12870.0005548780284390.154
2024-03-28iShares Russell 2000 ETF2.35430.0093412951619920.0483
2024-03-31Vanguard Institutional Extnd Mkt Idx Tr1.38390.00342427377116210.4811
2024-02-29TIAA-CREF Quant Small-Cap Equity Instl1.09330.09291917660386502.0569
2024-01-31Fidelity Small Cap Index0.97390.00811708312271971.6178
2024-02-29Delaware Healthcare I0.91220.312160000000
2024-03-28iShares Russell 2000 Growth ETF0.72030.0161263401621295.1719
2024-03-31State St Russell Sm/Mid Cp® Indx NL Cl C0.63150.00381107706897008.8113
2024-02-29Fidelity Extended Market Index0.54620.0038958096-4642-0.4822
2024-02-29Voya Small Company Port I0.46690.425818902160271.9962
2024-03-31BlackRock Advantage Small Cap Core Instl0.41220.029572295200
2024-03-31Vanguard Russell 2000 ETF0.36380.0093638071205973.3357
2024-03-31State St Russell Sm Cap® Indx SL Cl I0.35340.009461986700
2024-02-29Voya Small Company I0.32040.4228562041111082.0162
2023-12-31NT R2000 Index Fund - NL0.29270.0103513395357977.4952
2024-03-31Voya Small Cap Core Trust0.28490.3591499790-115332-18.7495
2024-03-31Voya MI Dynamic Small Cap0.28490.3591499790-115332-18.7495
2023-12-31Bridgeway Ultra-Small Company Market0.27080.37074750005000011.7647
2023-09-30BlackRock Extended Mkt Composite0.25210.003444217829940.6817
2023-12-31NT R2000 Growth Index Fund - NL0.23960.016542022200
Total 15.2862.464926812078+140945+0.5%

3.3. Insider Transactions

Insiders are holding 2.106% of the shares of Rigel Pharmaceuticals Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-02-02David A SantosSELL53881.66
2023-02-02Dean L SchornoSELL53891.66
2022-06-09Raul R RodriguezBUY10000000.69

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Rigel Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.086-0.0860%-0.251+193%-0.158+84%-0.135+58%
Book Value Per Share---0.163-0.1630%-0.078-52%0.087-289%0.320-151%
Current Ratio--1.8641.8640%1.777+5%2.059-9%3.956-53%
Debt To Asset Ratio--1.2441.2440%1.101+13%0.898+39%0.563+121%
Debt To Equity Ratio----0%-0%1.699-100%1.001-100%
Dividend Per Share----0%-0%-0%-0%
Eps---0.143-0.1430%-0.334+133%-0.226+58%-0.318+123%
Free Cash Flow Per Share---0.118-0.1180%-0.423+258%-0.212+79%-0.282+138%
Free Cash Flow To Equity Per Share---0.014-0.0140%-0.386+2748%-0.085+528%-0.091+574%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--1.333--------
Intrinsic Value_10Y_min---0.673--------
Intrinsic Value_1Y_max---0.105--------
Intrinsic Value_1Y_min---0.230--------
Intrinsic Value_3Y_max---0.134--------
Intrinsic Value_3Y_min---0.555--------
Intrinsic Value_5Y_max--0.056--------
Intrinsic Value_5Y_min---0.727--------
Market Cap210485990.400-21%254337238.400254337238.4000%263107488.000-3%394310422.016-35%440266529.920-42%
Net Profit Margin---0.215-0.2150%-0.512+139%-0.450+110%-3.742+1643%
Operating Margin---0.156-0.1560%-0.451+189%-0.420+169%-3.786+2329%
Operating Ratio--1.1751.1750%1.451-19%1.424-17%7.131-84%
Pb Ratio-7.348+17%-8.879-8.8790%-19.323+118%2.424-466%3.906-327%
Pe Ratio-8.389+17%-10.137-10.1370%-4.492-56%-13.365+32%-10.202+1%
Price Per Share1.200-21%1.4501.4500%1.500-3%2.248-35%2.510-42%
Price To Free Cash Flow Ratio-10.147+17%-12.261-12.2610%-3.546-71%10.498-217%0.370-3412%
Price To Total Gains Ratio-14.006+17%-16.924-16.9240%-5.981-65%-37.581+122%-16.016-5%
Quick Ratio--2.0962.0960%2.028+3%2.723-23%6.259-67%
Return On Assets---0.214-0.2140%-0.459+114%-0.301+41%-0.453+112%
Return On Equity----0%-0%-0.5440%-0.6670%
Total Gains Per Share---0.086-0.0860%-0.251+193%-0.158+84%-0.135+58%
Usd Book Value---28644000.000-28644000.0000%-13616000.000-52%15191000.000-289%56113200.000-151%
Usd Book Value Change Per Share---0.086-0.0860%-0.251+193%-0.158+84%-0.135+58%
Usd Book Value Per Share---0.163-0.1630%-0.078-52%0.087-289%0.320-151%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.143-0.1430%-0.334+133%-0.226+58%-0.318+123%
Usd Free Cash Flow---20743000.000-20743000.0000%-74208000.000+258%-37222400.000+79%-49458300.000+138%
Usd Free Cash Flow Per Share---0.118-0.1180%-0.423+258%-0.212+79%-0.282+138%
Usd Free Cash Flow To Equity Per Share---0.014-0.0140%-0.386+2748%-0.085+528%-0.091+574%
Usd Market Cap210485990.400-21%254337238.400254337238.4000%263107488.000-3%394310422.016-35%440266529.920-42%
Usd Price Per Share1.200-21%1.4501.4500%1.500-3%2.248-35%2.510-42%
Usd Profit---25091000.000-25091000.0000%-61596000.000+145%-40307600.000+61%-56159800.000+124%
Usd Revenue--116882000.000116882000.0000%120242000.000-3%110853800.000+5%66079000.000+77%
Usd Total Gains Per Share---0.086-0.0860%-0.251+193%-0.158+84%-0.135+58%
 EOD+2 -6MRQTTM+0 -0YOY+21 -105Y+22 -1010Y+21 -11

4.2. Fundamental Score

Let's check the fundamental score of Rigel Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-8.389
Price to Book Ratio (EOD)Between0-1-7.348
Net Profit Margin (MRQ)Greater than0-0.215
Operating Margin (MRQ)Greater than0-0.156
Quick Ratio (MRQ)Greater than12.096
Current Ratio (MRQ)Greater than11.864
Debt to Asset Ratio (MRQ)Less than11.244
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-0.214
Total3/10 (30.0%)

4.3. Technical Score

Let's check the technical score of Rigel Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5051.533
Ma 20Greater thanMa 501.142
Ma 50Greater thanMa 1001.317
Ma 100Greater thanMa 2001.303
OpenGreater thanClose1.180
Total3/5 (60.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets117,225
Total Liabilities145,869
Total Stockholder Equity-28,644
 As reported
Total Liabilities 145,869
Total Stockholder Equity+ -28,644
Total Assets = 117,225

Assets

Total Assets117,225
Total Current Assets99,266
Long-term Assets17,959
Total Current Assets
Cash And Cash Equivalents 32,786
Short-term Investments 24,147
Net Receivables 30,550
Inventory 5,522
Other Current Assets 6,261
Total Current Assets  (as reported)99,266
Total Current Assets  (calculated)99,266
+/-0
Long-term Assets
Property Plant Equipment 1,026
Intangible Assets 13,878
Long-term Assets Other 3,055
Long-term Assets  (as reported)17,959
Long-term Assets  (calculated)17,959
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities53,267
Long-term Liabilities92,602
Total Stockholder Equity-28,644
Total Current Liabilities
Short-term Debt 7,921
Short Long Term Debt 7,229
Accounts payable 7,142
Other Current Liabilities 21,165
Total Current Liabilities  (as reported)53,267
Total Current Liabilities  (calculated)43,457
+/- 9,810
Long-term Liabilities
Long term Debt 52,373
Capital Lease Obligations 977
Long-term Liabilities Other 39,944
Long-term Liabilities  (as reported)92,602
Long-term Liabilities  (calculated)93,294
+/- 692
Total Stockholder Equity
Common Stock175
Retained Earnings -1,407,550
Accumulated Other Comprehensive Income 8
Other Stockholders Equity 1,378,723
Total Stockholder Equity (as reported)-28,644
Total Stockholder Equity (calculated)-28,644
+/-0
Other
Capital Stock175
Cash and Short Term Investments 56,933
Common Stock Shares Outstanding 174,017
Current Deferred Revenue17,039
Liabilities and Stockholders Equity 117,225
Net Debt 27,793
Net Invested Capital 30,958
Net Working Capital 45,999
Property Plant and Equipment Gross 2,730
Short Long Term Debt Total 60,579



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-312005-12-312004-12-312003-12-312002-12-312001-12-312000-12-311999-12-31
> Total Assets 
17,169
64,262
46,448
44,342
55,524
78,822
147,668
113,240
115,789
143,858
140,744
186,695
257,106
310,043
226,058
154,135
131,747
78,134
119,111
139,109
147,569
110,378
167,328
134,279
117,225
117,225134,279167,328110,378147,569139,109119,11178,134131,747154,135226,058310,043257,106186,695140,744143,858115,789113,240147,66878,82255,52444,34246,44864,26217,169
   > Total Current Assets 
8,530
54,683
36,533
36,863
50,113
74,239
142,596
108,014
111,130
138,087
135,968
179,926
250,233
302,458
220,075
150,537
129,024
76,214
117,433
136,987
119,005
88,983
154,467
115,903
99,266
99,266115,903154,46788,983119,005136,987117,43376,214129,024150,537220,075302,458250,233179,926135,968138,087111,130108,014142,59674,23950,11336,86336,53354,6838,530
       Cash And Cash Equivalents 
5,836
49,030
11,488
26,535
9,621
10,495
76,779
47,727
44,503
46,005
14,717
8,877
18,633
33,484
20,854
15,203
43,456
17,632
38,290
76,322
22,521
30,373
18,890
24,459
32,786
32,78624,45918,89030,37322,52176,32238,29017,63243,45615,20320,85433,48418,6338,87714,71746,00544,50347,72776,77910,4959,62126,53511,48849,0305,836
       Short-term Investments 
0
3,964
21,927
756
36,879
60,932
61,417
56,744
63,793
88,472
118,601
168,418
229,007
264,757
191,121
127,956
82,820
57,134
77,461
52,215
75,557
26,954
106,077
33,747
24,147
24,14733,747106,07726,95475,55752,21577,46157,13482,820127,956191,121264,757229,007168,418118,60188,47263,79356,74461,41760,93236,87975621,9273,9640
       Net Receivables 
2,348
663
1,153
7,678
1,287
699
1,827
1,390
442
0
0
0
0
0
5,750
5,750
203
0
0
4,077
10,111
15,973
15,472
40,320
30,550
30,55040,32015,47215,97310,1114,077002035,7505,750000004421,3901,8276991,2877,6781,1536632,348
       Other Current Assets 
346
1,026
1,965
1,894
2,326
2,113
2,573
2,153
2,392
3,610
2,650
2,631
2,593
4,217
2,350
1,628
2,545
1,448
1,682
3,479
9,462
14,045
7,412
8,259
6,261
6,2618,2597,41214,0459,4623,4791,6821,4482,5451,6282,3504,2172,5932,6312,6503,6102,3922,1532,5732,1132,3261,8941,9651,026346
   > Long-term Assets 
8,639
9,579
9,915
7,479
5,411
4,583
5,072
5,226
4,659
5,771
4,776
6,769
6,873
7,585
5,983
3,598
2,723
1,920
1,678
2,122
28,564
21,395
12,861
18,376
17,959
17,95918,37612,86121,39528,5642,1221,6781,9202,7233,5985,9837,5856,8736,7694,7765,7714,6595,2265,0724,5835,4117,4799,9159,5798,639
       Property Plant Equipment 
8,398
9,338
8,440
5,206
3,544
2,813
3,457
2,975
2,560
3,567
2,291
4,534
4,882
5,826
4,455
2,509
1,613
1,156
875
1,387
27,868
20,571
11,887
2,787
1,026
1,0262,78711,88720,57127,8681,3878751,1561,6132,5094,4555,8264,8824,5342,2913,5672,5602,9753,4572,8133,5445,2068,4409,3388,398
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
14,949
13,878
13,87814,94900000000000000000000000
       Long-term Assets Other 
241
241
1,475
2,273
1,867
1,770
1,615
2,251
2,099
2,204
2,485
2,235
1,991
1,759
1,528
1,089
1,110
764
803
735
696
824
974
640
3,055
3,0556409748246967358037641,1101,0891,5281,7591,9912,2352,4852,2042,0992,2511,6151,7701,8672,2731,475241241
> Total Liabilities 
16,413
15,252
17,507
18,901
15,551
26,521
39,080
26,011
33,607
39,693
30,877
20,564
20,957
20,947
17,807
25,889
40,366
23,107
18,465
29,232
93,754
76,352
136,954
147,895
145,869
145,869147,895136,95476,35293,75429,23218,46523,10740,36625,88917,80720,94720,95720,56430,87739,69333,60726,01139,08026,52115,55118,90117,50715,25216,413
   > Total Current Liabilities 
9,520
8,056
10,162
14,370
8,054
11,418
23,647
11,238
16,112
24,151
17,773
11,326
11,527
12,204
10,294
14,025
33,796
22,588
18,337
27,734
58,212
40,841
63,554
65,211
53,267
53,26765,21163,55440,84158,21227,73418,33722,58833,79614,02510,29412,20411,52711,32617,77324,15116,11211,23823,64711,4188,05414,37010,1628,0569,520
       Short-term Debt 
2,176
2,952
3,171
3,388
2,259
1,321
1,070
1,269
990
1,339
1,061
755
0
7,717
0
2,803
3,005
3,222
284
0
7,272
8,621
9,892
1,133
7,921
7,9211,1339,8928,6217,27202843,2223,0052,80307,71707551,0611,3399901,2691,0701,3212,2593,3883,1712,9522,176
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7,229
7,229000000000000000000000000
       Accounts payable 
883
1,314
1,952
3,460
1,378
1,945
2,497
1,957
4,320
5,984
3,154
1,403
1,556
1,697
3,903
1,613
2,763
5,563
2,636
6,391
4,152
3,707
3,795
22,508
7,142
7,14222,5083,7953,7074,1526,3912,6365,5632,7631,6133,9031,6971,5561,4033,1545,9844,3201,9572,4971,9451,3783,4601,9521,314883
       Other Current Liabilities 
6,461
1,420
1,775
3,461
2,175
4,424
4,513
4,946
638
13,654
14,619
9,923
9,842
2,124
6,391
12,412
14,601
17,025
15,701
20,313
21,500
25,495
47,271
28,056
21,165
21,16528,05647,27125,49521,50020,31315,70117,02514,60112,4126,3912,1249,8429,92314,61913,6546384,9464,5134,4242,1753,4611,7751,4206,461
   > Long-term Liabilities 
6,893
7,196
7,345
4,531
7,497
15,103
15,433
14,773
17,495
15,542
13,104
9,238
9,430
8,743
7,513
11,864
6,570
519
128
1,498
35,542
35,511
73,400
82,684
92,602
92,60282,68473,40035,51135,5421,4981285196,57011,8647,5138,7439,4309,23813,10415,54217,49514,77315,43315,1037,4974,5317,3457,1966,893
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
9,810
19,815
19,914
39,448
0
039,44819,91419,8159,81000000000000000000000
       Other Liabilities 
0
1,435
3,102
2,218
6,261
14,322
14,301
13,691
16,711
13,489
12,221
9,193
9,430
8,743
7,513
11,864
6,570
519
128
1,498
6,502
5,045
52,727
0
0
0052,7275,0456,5021,4981285196,57011,8647,5138,7439,4309,19312,22113,48916,71113,69114,30114,3226,2612,2183,1021,4350
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
9,313
8,647
7,439
11,813
6,543
517
90
90
0
0
0
0
0
0000090905176,54311,8137,4398,6479,313000000000000
> Total Stockholder Equity
756
49,010
28,941
25,441
39,973
52,301
108,588
87,229
82,182
104,165
109,867
166,131
236,149
289,096
208,251
128,246
91,381
55,027
100,646
109,877
53,815
34,026
30,374
-13,616
-28,644
-28,644-13,61630,37434,02653,815109,877100,64655,02791,381128,246208,251289,096236,149166,131109,867104,16582,18287,229108,58852,30139,97325,44128,94149,010756
   Common Stock
3
37
38
46
15
20
25
25
31
37
52
52
71
87
88
88
91
100
147
167
168
169
172
174
175
175174172169168167147100918888877152523731252520154638373
   Retained Earnings -1,407,550-1,382,459-1,323,886-1,305,972-1,276,228-1,209,334-1,138,854-1,060,862-991,646-940,182-849,274-760,247-661,407-575,434-613,324-501,777-369,431-295,159-257,522-212,266-156,011-114,814-77,784-53,979-28,619
   Accumulated Other Comprehensive Income 
-5,814
-5,790
-2,408
-773
-213
-276
-118
13
198
396
-12
-38
6
82
47
-7
-44
-18
-82
-24
23
-4
-102
-153
8
8-153-102-423-24-82-18-44-747826-38-1239619813-118-276-213-773-2,408-5,790-5,814
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
897,479
1,049,174
1,057,390
1,068,347
1,082,980
1,115,807
1,239,435
1,319,068
1,329,852
1,339,833
1,354,190
1,368,822
0
01,368,8221,354,1901,339,8331,329,8521,319,0681,239,4351,115,8071,082,9801,068,3471,057,3901,049,174897,479000000000000
   Treasury Stock00000000000000000000-330000
   Other Stockholders Equity 
35,164
108,742
109,095
140,982
196,182
264,823
366,203
382,350
451,384
605,509
723,151
741,551
897,479
1,049,174
1,057,390
1,068,347
1,082,980
1,115,807
1,239,435
1,319,068
1,329,852
1,339,833
1,354,190
1,368,822
1,378,723
1,378,7231,368,8221,354,1901,339,8331,329,8521,319,0681,239,4351,115,8071,082,9801,068,3471,057,3901,049,174897,479741,551723,151605,509451,384382,350366,203264,823196,182140,982109,095108,74235,164



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue116,882
Cost of Revenue-7,110
Gross Profit109,772109,772
 
Operating Income (+$)
Gross Profit109,772
Operating Expense-130,263
Operating Income-20,491-20,491
 
Operating Expense (+$)
Research Development24,522
Selling General Administrative111,063
Selling And Marketing Expenses0
Operating Expense130,263135,585
 
Net Interest Income (+$)
Interest Income2,023
Interest Expense-6,872
Other Finance Cost-800
Net Interest Income-4,049
 
Pretax Income (+$)
Operating Income-20,491
Net Interest Income-4,049
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-25,091-15,891
EBIT - interestExpense = -25,091
-22,819
-18,219
Interest Expense6,872
Earnings Before Interest and Taxes (EBIT)-18,219-18,219
Earnings Before Interest and Taxes (EBITDA)-16,981
 
After tax Income (+$)
Income Before Tax-25,091
Tax Provision-0
Net Income From Continuing Ops-24,427-25,091
Net Income-25,091
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses137,373
Total Other Income/Expenses Net-4,6004,049
 

Technical Analysis of Rigel
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Rigel. The general trend of Rigel is BEARISH with 28.6% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Rigel's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-28.6%) Bearish trend (28.6%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Rigel Pharmaceuticals Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 1.505 < 1.73 < 1.77.

The bearish price targets are: 1.17 > 1.01 > 0.9098.

Tweet this
Rigel Pharmaceuticals Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Rigel Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 5/14.
The longshort score for the Moving Averages is -4/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Rigel Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Rigel Pharmaceuticals Inc. The current macd is -0.0505775.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Rigel price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Rigel. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Rigel price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Rigel Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartRigel Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Rigel Pharmaceuticals Inc. The current adx is 30.98.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -3/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Rigel shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bearish trend. The ADX is declining, the bearish trend is weakening. Could be a potential reversal to the upside. -2
Rigel Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Rigel Pharmaceuticals Inc. The current sar is 1.013.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Rigel Pharmaceuticals Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Rigel Pharmaceuticals Inc. The current rsi is 51.53. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
  • Trending up: The RSI is trending up. +1
Rigel Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartRigel Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Rigel Pharmaceuticals Inc. The current phase is Overbought in bear market.

The long score for the Stochastic Oscillator is 6/6.
The longshort score for the Stochastic Oscillator is 6/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Rigel price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Rigel Pharmaceuticals Inc Daily Stochastic Oscillator ChartRigel Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Rigel Pharmaceuticals Inc. The current cci is 61.52.

Rigel Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartRigel Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Rigel Pharmaceuticals Inc. The current cmo is 19.00.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Rigel Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartRigel Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Rigel Pharmaceuticals Inc. The current willr is -9.52380952.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Rigel Pharmaceuticals Inc Daily Williams %R ChartRigel Pharmaceuticals Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Rigel Pharmaceuticals Inc. The current atr is 0.07362629.

Rigel Pharmaceuticals Inc Daily Average True Range (ATR) ChartRigel Pharmaceuticals Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Rigel Pharmaceuticals Inc. The current obv is 63,401,808.

Rigel Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartRigel Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Rigel Pharmaceuticals Inc. The current mfi is 29.33.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Rigel Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartRigel Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Rigel Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-14STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-15WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-21MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-27BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-29RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-04STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-09STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-18WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-19STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-23CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-24BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-31WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-02STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-06SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-15CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-21CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-26STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-20CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-26SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-04-01DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-04STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-10WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-22RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-04-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-30WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-05-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-05-03WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside

6.3. Candlestick Patterns

Rigel Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Rigel Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5051.533
Ma 20Greater thanMa 501.142
Ma 50Greater thanMa 1001.317
Ma 100Greater thanMa 2001.303
OpenGreater thanClose1.180
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Rigel with someone you think should read this too:
  • Are you bullish or bearish on Rigel? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Rigel? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Rigel Pharmaceuticals Inc

I send you an email if I find something interesting about Rigel Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Rigel Pharmaceuticals Inc.

Receive notifications about Rigel Pharmaceuticals Inc in your mailbox!